secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001935979-23-000033
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven Q1 net loss $70.5M; cash $392M; pipeline progress, TYK2/JAK1 license acquired
--------------------------------------------------------------------------------

- Net loss of $70.5M ($1.03/share); non-GAAP adjusted net loss $66.7M ($0.98/share).
- Cash and marketable securities $392.0M at March 31, 2023, down from $467.9M at Dec 31, 2022.
- Acquired exclusive global rights (ex-China) to TYK2/JAK1 inhibitor BHV-8000; Phase 1 start planned in 2023.
- Appointed Nick Kozauer (former FDA Division Director) as SVP of Clinical Development and Regulatory Strategy.
- Anticipates H2 2023: Phase 2/3 for BHV-7000 in epilepsy/bipolar; IND submissions for BHV-7010, -2100, -1300.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597923000033/0001935979-23-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597923000033/bhvn-20230512.htm
  HTML page:      https://secwatch.observer/filing/0001935979-23-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer